Phase 3 N=443 Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study
Inflammatory Bowel Disease · Ulcerative Colitis
Primary: Incidence of Treatment Emergent AEs — 273 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=103 Altitude Sickness Prevention and Efficacy of Comparative Treatments
Acute Mountain Sickness
Primary: Number of Participants With Acute Mountain Sickness — 24; 22; 15 Count of participants
Phase 3 N=527 A Moderate to Severe Rheumatoid Arthritis Study
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response - Placebo Versus Baricitinib 4 mg — 27.3; 55.4 Percentage of Participants…
Phase 3 N=507 Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine
Type 1 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26 — -0.42; -0.47 percentage of HbA1c
Phase 3 N=505 Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Type 2 Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 26 — -0.92; -0.85 percentage of HbA1c
Phase 3 N=236 Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes
Diabetes · Diabetes Mellitus, Type 2
Primary: Change From Baseline in HbA1c — 7.93; 7.92; 6.78; 7.7 Percentage of glycosylated haemoglobin
Phase 3 N=321 A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
Catecholamine-resistant Hypotension (CRH) · Distributive Shock · High Output Shock
Primary: An Increased MAP, Defined as Achievement of a Day 1 MAP at 3 Hours Following the Initiation of Study Drug, of ≥ 75 mmHg OR a 10 mmHg Increase in Baseline MAP — 114; 37…
Phase 3 N=307 A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Hematologic Remission (Complete Remission [CR]/Complete Remission With Incomplete Hematologic Recovery [CRi]) as Assessed by the Endpoint…
Phase 3 N=87 NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder (ADHD)
Primary: Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Score — 24.3; 17.3 score on a scale — p=<0.0001
Phase 3 N=710 A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
Nausea and Vomiting, Chemotherapy-Induced
Primary: Percentage of Participants Who Achieved a Complete Response in the Overall Phase (0-120 Hours) Following Initiation of the First Cycle of an Oxaliplatin Based Moderately…
Phase 3 N=735 A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
Systemic Lupus Erythematosus
Primary: Number of Participants With Adverse Events (AE) — 706; 617; 502; 441 Participants
Phase 3 N=17 Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis
Cystinosis
Primary: Mean White Blood Cell (WBC) Cystine Concentration at Each Visit — 3.1709; 2.2899; 1.8474; 2.3403 nmol 1/2 Cystine/mg protein
Phase 3 N=1,974 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Dyslipidemia
Primary: Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score — 0.1206; 0.1134 Z score
Phase 3 N=80 The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
Weight Loss · Obesity
Primary: Energy Intake — 1016.1; 245.1 kcal/day — p=0.01
Phase 3 N=20 Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia
Coronary Artery Disease · Acute Myocardial Ischemia
Primary: Left Ventricular Global Strain Rate — 18; 23 percentage of change